Resistance to Abemaciclib is Associated With Increased Metastatic Potential and Lysosomal Protein Deregulation in Breast Cancer Cells Scheidemann ER, Demas DM, Hou C, Ma J, He W, Sharma G, Schultz E, Weilbaecher KN, Shajahan-Haq AN Mol Carcinog 2024 Feb;63(2):209-223
Transferrin Receptor in Primary and Metastatic Breast Cancer: Evaluation of Expression and Experimental Modulation to Improve Molecular Targeting Fontana F, Esser AK, Egbulefu C, Karmakar P, Su X, Allen JS, Xu Y, Davis JL, Gabay A, Xiang J, Kwakwa KA, Manion B, Bakewell S, Li S, Park H, Lanza GM, Achilefu S, Weilbaecher KN PLoS One 2023 Dec;18(12):e0293700
p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy Faget DV, Luo X, Inkman MJ, Ren Q, Su X, Ding K, Waters MR, Raut GK, Pandey G, Dodhiawala PB, Ramalho-Oliveira R, Ye J, Cole T, Murali B, Zheleznyak A, Shokeen M, Weiss KR, Monahan JB, DeSelm CJ, Lee AV, Oesterreich S, Weilbaecher KN, Zhang J, DeNardo DG, Stewart SA Cancer Discov 2023 Jun;13(6):1454-1477
Frequency of Hepatic Metastatic Disease in Patients With Stage IV Breast Cancer is Similar for Steatotic and Non-Steatotic Livers Haq A, Fraum TJ, Tao Y, Dehdashti F, LeBlanc M, Hoegger MJ, Luo J, Weilbaecher K, Peterson LL Breast Cancer (Auckl) 2023 May;17:11782234231166476
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, Suresh R, Ademuyiwa FO, Rigden C, Rearden TP, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya LF, Peterson LL, Wang X, Luo SJ, Zhou K, Du P, Jia S, King BL, Krishnamurthy J, Ma CX Clin Cancer Res 2023 May;29(9):1719-1729
A Phase II Study of Palbociclib Plus Letrozole Plus Trastuzumab as Neoadjuvant Treatment for Clinical Stages II and III ER+ HER2+ Breast Cancer (PALTAN) Ademuyiwa FO, Northfelt DW, O’Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX NPJ Breast Cancer 2023 Jan;9(1):1
Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19 Xiang J, Lu M, Shi M, Cheng X, Kwakwa KA, Davis JL, Su X, Bakewell SJ, Zhang Y, Fontana F, Xu Y, Veis DJ, DiPersio JF, Ratner L, Sanderson RD, Noseda A, Mollah S, Li J, Weilbaecher KN J Virol 2022 Apr;96(7):e0005722
Machine Learning-Based Scoring Models to Predict Hematopoietic Stem Cell Mobilization in Allogeneic Donors Xiang J, Shi M, Fiala MA, Gao F, Rettig MP, Uy GL, Schroeder MA, Weilbaecher KN, Stockerl-Goldstein KE, Mollah S, DiPersio JF Blood Adv 2022 Apr;6(7):1991-2000
A Phase II Trial of an Alternative Schedule of Palbociclib and Embedded Serum TK1 Analysis Krishnamurthy J, Luo J, Suresh R, Ademuyiwa F, Rigden C, Rearden T, Clifton K, Weilbaecher K, Frith A, Roshal A, Tandra PK, Cherian M, Summa T, Haas B, Thomas S, Hernandez-Aya L, Bergqvist M, Peterson L, Ma CX NPJ Breast Cancer 2022 Mar;8(1):35
A Randomized Feasibility Study Evaluating Temozolomide Circadian Medicine in Patients With Glioma Damato AR, Katumba RGN, Luo J, Atluri H, Talcott GR, Govindan A, Slat EA, Weilbaecher KN, Tao Y, Huang J, Butt OH, Ansstas G, Johanns TM, Chheda MG, Herzog ED, Rubin JB, Campian JL Neurooncol Pract 2022 Jan;9(3):193-200
Organ-on-a-Chip Model of Vascularized Human Bone Marrow Niches Glaser DE, Curtis MB, Sariano PA, Rollins ZA, Shergill BS, Anand A, Deely AM, Shirure VS, Anderson L, Lowen JM, Ng NR, Weilbaecher K, Link DC, George SC Biomaterials 2022 Jan;280:121245
Yoga Therapy During Chemotherapy for Early-Stage and Locally Advanced Breast Cancer Greaney SK, Amin N, Prudner BC, Compernolle M, Sandell LJ, Tebb SC, Weilbaecher KN, Abeln P, Luo J, Tao Y, Hirbe AC, Peterson LL Integr Cancer Ther 2022 Jan-Dec;21:15347354221137285
Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists Ademuyiwa FO, Salyer P, Tao Y, Luo J, Hensing WL, Afolalu A, Peterson LL, Weilbaecher K, Housten AJ, Baumann AA, Desai M, Jones S, Linnenbringer E, Plichta J, Bierut L J Clin Oncol 2021 Dec;39(36):4020-4028
Breast Cancer-Derived GM-CSF Regulates Arginase 1 in Myeloid Cells to Promote an Immunosuppressive Microenvironment Su X, Xu Y, Fox GC, Xiang J, Kwakwa KA, Davis JL, Belle JI, Lee WC, Wong WH, Fontana F, Hernandez-Aya LF, Kobayashi T, Tomasson HM, Su J, Bakewell SJ, Stewart SA, Egbulefu C, Karmakar P, Meyer MA, Veis DJ, DeNardo DG, Lanza GM, Achilefu S, Weilbaecher KN J Clin Invest 2021 Oct;131(20):e145296
Disseminated Tumour Cells From the Bone Marrow of Early Breast Cancer Patients: Results From an International Pooled Analysis Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Ryden L, Fehm T, Aft R, Sola M, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching PA, Ferno M, Krawczyk N, Weilbaecher K, Margeli M, Hahn M, Jueckstock J, Domschke C, Bidard FC, Kasimir-Bauer S, Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Klein CA, Wallwiener D, Janni W, Pantel K Eur J Cancer 2021 Sep;154:128-137
Antibiotic-Induced Disturbances of the Gut Microbiota Result in Accelerated Breast Tumor Growth McKee AM, Kirkup BM, Madgwick M, Fowler WJ, Price CA, Dreger SA, Ansorge R, Makin KA, Caim S, Le Gall G, Paveley J, Leclaire C, Dalby M, Alcon-Giner C, Andrusaite A, Feng TY, Di Modica M, Triulzi T, Tagliabue E, Milling SWF, Weilbaecher KN, Rutkowski MR, Korcsmáros T, Hall LJ, Robinson SD iScience 2021 Aug;24(9):103012
Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple-Negative Breast Cancer Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M Breast Cancer Res Treat 2021 Aug;189(1):187-202
Management of Bone Metastasis and Cancer Treatment-Induced Bone Loss During the COVID-19 Pandemic: An International Perspective and Recommendations Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI, Juarez P, El Badri S, Ariaspinilla G, D’Oronzo S, Guise TA, Van Poznak C J Bone Oncol 2021 Aug;29:100375
Targeted Therapy to Beta3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases Fox GC, Su X, Davis JL, Xu Y, Kwakwa KA, Ross MH, Fontana F, Xiang J, Esser AK, Cordell E, Pagliai K, Dang HX, Sivapackiam J, Stewart SA, Maher CA, Bakewell SJ, Fitzpatrick JAJ, Sharma V, Achilefu S, Veis DJ, Lanza GM, Weilbaecher KN Mol Cancer Ther 2021 Jun;20(6):1183-1198
N-Cadherin in Osteolineage Cells Modulates Stromal Support of Tumor Growth Fontana F, Xiang J, Su X, Tycksen E, Nassau R, Fox G, Leanza G, Weilbaecher K, Civitelli R J Bone Oncol 2021 Mar;28:100356
Mutation Profile Differences in Younger and Older Patients With Advanced Breast Cancer Using Circulating Tumor DNA (CtDNA) Clifton K, Luo J, Tao Y, Saam J, Rich T, Roshal A, Frith A, Rigden C, Ademuyiwa F, Weilbaecher K, Hernandez-Aya L, Peterson LL, Bagegni N, Suresh R, Bose R, Opyrchal M, Wildes TM, Ma C Breast Cancer Res Treat 2021 Feb;185(3):639-646
In Vivo Tumorigenesis, Osteolytic Sarcomas, and Tumorigenic Cell Lines From Transgenic Mice Expressing the Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Viral Oncogene Lanigan LG, Hildreth BE 3rd, Dirksen WP, Simmons JK, Martin CK, Werbeck JL, Thudi NK, Papenfuss TL, Boyaka PN, Toribio RE, Ward JM, Weilbaecher KN, Rosol TJ Am J Pathol 2021 Feb;191(2):335-352
Targeting Primary and Metastatic Uveal Melanoma With a G Protein Inhibitor Onken MD, Makepeace CM, Kaltenbronn KM, Choi J, Hernandez-Aya L, Weilbaecher KN, Piggott KD, Rao PK, Yuede CM, Dixon AJ, Osei-Owusu P, Cooper JA, Blumer KJ J Biol Chem 2021 Jan-Jun;296:100403
Hepatic Lipids Promote Liver Metastasis Li Y, Su X, Rohatgi N, Zhang Y, Brestoff JR, Shoghi KI, Xu Y, Semenkovich CF, Harris CA, Peterson LL, Weilbaecher KN, Teitelbaum SL, Zou W JCI Insight 2020 Sep;5(17):e136215
Nanotherapy Delivery of c-MYC Inhibitor Targets Protumor Macrophages and Preserves Antitumor Macrophages in Breast Cancer Esser AK, Ross MH, Fontana F, Su X, Gabay A, Fox GC, Xu Y, Xiang J, Schmieder AH, Yang X, Cui G, Scott M, Achilefu S, Chauhan J, Fletcher S, Lanza GM, Weilbaecher KN Theranostics 2020 Jun;10(17):7510-7526
Parathyroid Hormone-Related Protein Promotes Bone Loss in T-Cell Leukemia as Well as in Solid Tumors Kohart NA, Elshafae SM, Demirer AA, Dirksen WP, Breitbach JT, Shu ST, Xiang J, Weilbaecher KN, Rosol TJ Leuk Lymphoma 2020 Feb;61(2):409-419
Assessing the Effectiveness of the National Comprehensive Cancer Network Genetic Testing Guidelines in Identifying African American Breast Cancer Patients With Deleterious Genetic Mutations Ademuyiwa FO, Salyer P, Ma Y, Fisher S, Colditz G, Weilbaecher KN, Bierut LJ Breast Cancer Res Treat 2019 Nov;178(1):151-159
HTLV-1 Viral Oncogene HBZ Drives Bone Destruction in Adult T Cell Leukemia Xiang J, Rauch DA, Huey DD, Panfil AR, Cheng X, Esser AK, Su X, Harding JC, Xu Y, Fox GC, Fontana F, Kobayashi T, Su J, Sundaramoorthi H, Wong WH, Jia Y, Rosol TJ, Veis DJ, Green PL, Niewiesk S, Ratner L, Weilbaecher KN JCI Insight 2019 Oct;4(19):e128713
Mouse Model Recapitulates the Phenotypic Heterogeneity of Human Adult T-Cell Leukemia/Lymphoma in Bone Kohart NA, Elshafae SM, Supsahvad W, Alasonyalilar-Demirer A, Panfil AR, Xiang J, Dirksen WP, Veis DJ, Green PL, Weilbaecher KN, Rosol TJ J Bone Oncol 2019 Aug;19:100257
Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation Heo GS, Zhao Y, Sultan D, Zhang X, Detering L, Luehmann HP, Zhang X, Li R, Choksi A, Sharp S, Levingston S, Primeau T, Reichert DE, Sun G, Razani B, Li S, Weilbaecher KN, Dehdashti F, Wooley KL, Liu Y ACS Appl Mater Interfaces 2019 Jun;11(22):19669-19678
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX J Natl Compr Canc Netw 2019 Feb;17(2):141-147
Circulating Receptor Activator of Nuclear Factor-KappaB (RANK), RANK Ligand (RANKL), and Mammographic Density in Premenopausal Women Toriola AT, Appleton CM, Zong X, Luo J, Weilbaecher K, Tamimi RM, Colditz GA Cancer Prev Res (Phila) 2018 Dec;11(12):789-796
Inhibition of the Stromal P38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss Murali B, Ren Q, Luo X, Faget DV, Wang C, Johnson RM, Gruosso T, Flanagan KC, Fu Y, Leahy K, Alspach E, Su X, Ross MH, Burnette B, Weilbaecher KN, Park M, Mbalaviele G, Monahan JB, Stewart SA Cancer Res 2018 Oct;78(19):5618-5630
The Beta3-Integrin Endothelial Adhesome Regulates Microtubule-Dependent Cell Migration Atkinson SJ, Gontarczyk AM, Alghamdi AA, Ellison TS, Johnson RT, Fowler WJ, Kirkup BM, Silva BC, Harry BE, Schneider JG, Weilbaecher KN, Mogensen MM, Bass MD, Parsons M, Edwards DR, Robinson SD EMBO Rep 2018 Jul;19(7):e44578
Balixafortide Plus Eribulin in HER2-Negative Metastatic Breast Cancer: A Phase 1, Single-Arm, Dose-Escalation Trial Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J Lancet Oncol 2018 Jun;19(6):812-824
Perfusion-Based Fluorescence Imaging Method Delineates Diverse Organs and Identifies Multifocal Tumors Using Generic Near-Infrared Molecular Probes Miller J, Wang ST, Orukari I, Prior J, Sudlow G, Su X, Liang K, Tang R, Hillman EMC, Weilbaecher KN, Culver JP, Berezin MY, Achilefu S J Biophotonics 2018 Apr;11(4):e201700232
Breast and Pancreatic Cancer Interrupt IRF8-Dependent Dendritic Cell Development to Overcome Immune Surveillance Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG Nat Commun 2018 Mar;9(1):1250
Radionuclides Transform Chemotherapeutics Into Phototherapeutics for Precise Treatment of Disseminated Cancer Kotagiri N, Cooper ML, Rettig M, Egbulefu C, Prior J, Cui G, Karmakar P, Zhou M, Yang X, Sudlow G, Marsala L, Chanswangphuwana C, Lu L, Habimana-Griffin L, Shokeen M, Xu X, Weilbaecher K, Tomasson M, Lanza G, DiPersio JF, Achilefu S Nat Commun 2018 Jan;9(1):275
Bone-Induced Expression of Integrin Beta3 Enables Targeted Nanotherapy of Breast Cancer Metastases Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack J, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN Cancer Res 2017 Nov;77(22):6299-6312
HTLV-1 Viral Oncogene HBZ Induces Osteolytic Bone Disease in Transgenic Mice Esser AK, Rauch DA, Xiang J, Harding JC, Kohart NA, Ross MH, Su X, Wu K, Huey D, Xu Y, Vij K, Green PL, Rosol TJ, Niewiesk S, Ratner L, Weilbaecher KN Oncotarget 2017 Aug;8(41):69250-69263
Differences in the Mutational Landscape of Triple-Negative Breast Cancer in African Americans and Caucasians Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX Breast Cancer Res Treat 2017 Feb;161(3):491-499
Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma Fontana F, Ge X, Su X, Hathi D, Xiang J, Cenci S, Civitelli R, Shoghi KI, Akers WJ, D’avignon A, Weilbaecher KN, Shokeen M Clin Cancer Res 2017 Jan;23(2):416-429
Antagonizing Integrin Beta3 Increases Immunosuppression in Cancer Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN Cancer Res 2016 Jun;76(12):3484-95
Dickkopf-Related Protein 1 (Dkk1) Regulates the Accumulation and Function of Myeloid Derived Suppressor Cells in Cancer D’Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R J Exp Med 2016 May;213(5):827-840
Effects of Neoadjuvant Chemotherapy With or Without Zoledronic Acid on Pathological Response: A Meta-Analysis of Randomised Trials Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JW, Kohno N Eur J Cancer 2016 Feb;54:57-63
Dual-Therapy With AlphavBeta3-Targeted Sn2 Lipase-Labile Fumagillin-Prodrug Nanoparticles and Zoledronic Acid in the Vx2 Rabbit Tumor Model Esser AK, Schmieder AH, Ross MH, Xiang J, Su X, Cui G, Zhang H, Yang X, Allen JS, Williams T, Wickline SA, Pan D, Lanza GM, Weilbaecher KN Nanomedicine 2016 Jan;12(1):201-11
Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, Gang M, Su X, Zamani A, Shi Y, Lavine KJ, Ornitz DM, Weilbaecher KN, Long F, Novack DV, Faccio R, Longmore GD, Stewart SA Cell Rep 2016 Jan;14(1):82-92
CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN Mol Cancer Ther 2015 Nov;14(11):2473-85
Suppression of Beta3-Integrin in Mice Triggers a Neuropilin-1-Dependent Change in Focal Adhesion Remodelling That Can Be Targeted to Block Pathological Angiogenesis Ellison TS, Atkinson SJ, Steri V, Kirkup BM, Preedy ME, Johnson RT, Ruhrberg C, Edwards DR, Schneider JG, Weilbaecher K, Robinson SD Dis Model Mech 2015 Sep;8(9):1105-1119
Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma Soodgupta D, Pan D, Cui G, Senpan A, Yang X, Lu L, Weilbaecher KN, Prochownik EV, Lanza GM, Tomasson MH Mol Cancer Ther 2015 Jun;14(6):1286-94
Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O’Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH PLoS One 2015 May;10(5):e0127828
Comparative Effectiveness on Survival of Zoledronic Acid Versus Pamidronate in Multiple Myeloma Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, Colditz G, Carson K Leuk Lymphoma 2015 Mar;56(3):615-21
Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, McKenna CE, Croucher PI, Swarbrick A, Weilbaecher K, Phan TG, Rogers MJ Cancer Discov 2015 Jan;5(1):35-42
Thrombospondin-1 Regulates Bone Homeostasis Through Effects on Bone Matrix Integrity and Nitric Oxide Signaling in Osteoclasts Amend SR, Uluckan O, Hurchla M, Leib D, Novack DV, Silva M, Frazier W, Weilbaecher KN J Bone Miner Res 2015 Jan;30(1):106-15
Acute Depletion of Endothelial Beta3-Integrin Transiently Inhibits Tumor Growth and Angiogenesis in Mice Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD Circ Res 2014 Jan;114(1):79-91
A Randomized Phase II Trial Investigating the Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients With Metastatic Breast Cancer Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, Johnson F, Eby CS, Weilbaecher KN Clin Breast Cancer 2013 Dec;13(6):409-15
Role of WNT7B-Induced Noncanonical Pathway in Advanced Prostate Cancer Zheng D, Decker KF, Zhou T, Chen J, Qi Z, Jacobs K, Weilbaecher KN, Corey E, Long F, Jia L Mol Cancer Res 2013 May;11(5):482-93
Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ ACS Chem Biol 2013 Mar;8(3):578-587
Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis Via Unexpected Osteoclast Activation Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV Cancer Discov 2013 Feb;3(2):212-23
The Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable Oprozomib Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN Leukemia 2013 Feb;27(2):430-40
Very Late Antigen-4 (Alpha(4)beta(1) Integrin) Targeted PET Imaging of Multiple Myeloma Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH, Shokeen M PLoS One 2013;8(2):e55841
The ADP Receptor P2RY12 Regulates Osteoclast Function and Pathologic Bone Remodeling Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN J Clin Invest 2012 Oct;122(10):3579-92
Integrin Alpha(V)beta(3) as a PET Imaging Biomarker for Osteoclast Number in Mouse Models of Negative and Positive Osteoclast Regulation Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ Mol Imaging Biol 2012 Aug;14(4):500-8
Breast Cancer Cell Targeting by Prenylation Inhibitors Elucidated in Living Animals With a Bioluminescence Reporter Chinault SL, Prior JL, Kaltenbronn KM, Penly A, Weilbaecher KN, Piwnica-Worms D, Blumer KJ Clin Cancer Res 2012 Aug;18(15):4136-44
Effect of (Neo)adjuvant Zoledronic Acid on Disease-Free and Overall Survival in Clinical Stage II/III Breast Cancer Aft RL, Naughton M, Trinkaus K, Weilbaecher K Br J Cancer 2012 Jun;107(1):7-11
Hedgehog Signaling Inhibition Blocks Growth of Resistant Tumors Through Effects on Tumor Microenvironment Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN Cancer Res 2012 Feb;72(4):897-907
CD8+ T Cells Regulate Bone Tumor Burden Independent of Osteoclast Resorption Zhang K, Kim S, Cremasco V, Hirbe AC, Novack DV, Weilbaecher K, Faccio R Cancer Res 2011 Jul;71(14):4799-808
The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma Development in Mice Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN PLoS One 2010 Dec;5(12):e15755
A Gene Expression Signature That Predicts the Therapeutic Response of the Basal-Like Breast Cancer to Neoadjuvant Chemotherapy Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL Breast Cancer Res Treat 2010 Oct;123(3):691-699
A Role for the Epithelial Microenvironment at Tumor Boundaries: Evidence From Drosophila and Human Squamous Cell Carcinomas Vidal M, Salavaggione L, Ylagan L, Wilkins M, Watson M, Weilbaecher K, Cagan R Am J Pathol 2010 Jun;176(6):3007-14
Effect of Zoledronic Acid on Disseminated Tumour Cells in Women With Locally Advanced Breast Cancer: An Open Label, Randomised, Phase 2 Trial Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K Lancet Oncol 2010 May;11(5):421-8
Dissection of Platelet and Myeloid Cell Defects by Conditional Targeting of the Beta3-Integrin Subunit Morgan EA, Schneider JG, Baroni TE, Uluckan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN FASEB J 2010 Apr;24(4):1117-27
Targeting the AlphavBeta3 Integrin for Small-Animal PET/CT of Osteolytic Bone Metastases Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ J Nucl Med 2009 Nov;50(11):1873-80
The Bisphosphonate Zoledronic Acid Decreases Tumor Growth in Bone in Mice With Defective Osteoclasts Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K Bone 2009 May;44(5):908-16
CD47 Regulates Bone Mass and Tumor Metastasis to Bone Uluckan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN Cancer Res 2009 Apr;69(7):3196-204
Interferon-{gamma} Targets Cancer Cells and Osteoclasts to Prevent Tumor-Associated Bone Loss and Bone Metastases Xu Z, Hurchla MA, Deng H, Uluckan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN J Biol Chem 2009 Feb;284(7):4658-66
Multiple Facets of JunD Gene Expression Are Atypical Among AP-1 Family Members Hernandez JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K Oncogene 2008 Aug;27(35):4757-67
APT102, a Novel Adpase, Cooperates With Aspirin to Disrupt Bone Metastasis in Mice Uluckan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K J Cell Biochem 2008 Jul;104(4):1311-1323
RelB Is the NF-KappaB Subunit Downstream of NIK Responsible for Osteoclast Differentiation Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, O’Neal J, Zou W, Weilbaecher KN, Faccio R, Novack DV Proc Natl Acad Sci U S A 2008 Mar;105(10):3897-902
A Non-Tumor Suppressor Role for Basal p19ARF in Maintaining Nucleolar Structure and Function Apicelli AJ, Maggi LB Jr, Hirbe AC, Miceli AP, Olanich ME, Schulte-Winkeler CL, Saporita AJ, Kuchenreuther M, Sanchez J, Weilbaecher K, Weber JD Mol Cell Biol 2008 Feb;28(3):1068-80
Isolation and Molecular Profiling of Bone Marrow Micrometastases Identifies TWIST1 as a Marker of Early Tumor Relapse in Breast Cancer Patients Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL Clin Cancer Res 2007 Sep;13(17):5001-9
Disruption of CXCR4 Enhances Osteoclastogenesis and Tumor Growth in Bone Hirbe AC, Rubin J, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN Proc Natl Acad Sci U S A 2007 Aug;104(35):14062-7
Granulocyte Colony-Stimulating Factor Enhances Bone Tumor Growth in Mice in an Osteoclast-Dependent Manner Hirbe AC, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K Blood 2007 Apr;109(8):3424-31
Noninvasive Imaging of Osteoclasts in Parathyroid Hormone-Induced Osteolysis Using a 64Cu-Labeled RGD Peptide Sprague JE, Kitaura H, Zou W, Ye Y, Achilefu S, Weilbaecher KN, Teitelbaum SL, Anderson CJ J Nucl Med 2007 Feb;48(2):311-8
HTLV-1 Tax Transgenic Mice Develop Spontaneous Osteolytic Bone Metastases Prevented by Osteoclast Inhibition Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K Blood 2005 Dec;106(13):4294-302
Platelet and Osteoclast Beta3 Integrins Are Critical for Bone Metastasis Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN Proc Natl Acad Sci U S A 2003 Nov;100(24):14205-10
Comparison of Five Antibodies as Markers in the Diagnosis of Melanoma in Cytologic Preparations Sheffield MV, Yee H, Dorvault CC, Weilbaecher KN, Eltoum IA, Siegal GP, Fisher DE, Chhieng DC Am J Clin Pathol 2002 Dec;118(6):930-6
The Melanocyte-Specific Isoform of the Microphthalmia Transcription Factor Affects the Phenotype of Human Melanoma Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, Weilbaecher KN, Schlegel W, Valent P, Wrba F, Pehamberger H, Fisher D, Jansen B Cancer Res 2002 Apr;62(7):2098-103
Microphthalmia Transcription Factor: A Sensitive and Specific Marker for Malignant Melanoma in Cytologic Specimens Dorvault CC, Weilbaecher KN, Yee H, Fisher DE, Chiriboga LA, Xu Y, Chhieng DC Cancer 2001 Oct;93(5):337-43
Linkage of M-CSF Signaling to Mitf, TFE3, and the Osteoclast Defect in Mitf(Mi/Mi) Mice Weilbaecher KN, Motyckova G, Huber WE, Takemoto CM, Hemesath TJ, Xu Y, Hershey CL, Dowland NR, Wells AG, Fisher DE Mol Cell 2001 Oct;8(4):749-58
Microphthalmia Transcription Factor: Not a Sensitive or Specific Marker for the Diagnosis of Desmoplastic Melanoma and Spindle Cell (Non-Desmoplastic) Melanoma Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE Am J Dermatopathol 2001 Jun;23(3):185-9
Linking Osteopetrosis and Pycnodysostosis: Regulation of Cathepsin K Expression by the Microphthalmia Transcription Factor Family Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, Fisher DE Proc Natl Acad Sci U S A 2001 May;98(10):5798-803
Clear Cell Sarcoma Shows Immunoreactivity for Microphthalmia Transcription Factor: Further Evidence for Melanocytic Differentiation Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE Mod Pathol 2001 Jan;14(1):6-9
Microphthalmia Transcription Factor Expression in Cutaneous Benign, Malignant Melanocytic, and Nonmelanocytic Tumors King R, Googe PB, Weilbaecher KN, Mihm MC Jr, Fisher DE Am J Surg Pathol 2001 Jan;25(1):51-7
Microphthalmia Transcription Factor. A Sensitive and Specific Melanocyte Marker for Melanoma Diagnosis King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE Am J Pathol 1999 Sep;155(3):731-8
Alpha-Melanocyte-Stimulating Hormone Signaling Regulates Expression of Microphthalmia, a Gene Deficient in Waardenburg Syndrome Price ER, Horstmann MA, Wells AG, Weilbaecher KN, Takemoto CM, Landis MW, Fisher DE J Biol Chem 1998 Dec;273(49):33042-7
Age-Resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3 Weilbaecher KN, Hershey CL, Takemoto CM, Horstmann MA, Hemesath TJ, Tashjian AH, Fisher DE J Exp Med 1998 Mar;187(5):775-85
Porphyria Cutanea Tarda and Hepatitis C Virus Infection in a Patient With Acute Liver Failure Jasmer RM, Larson MS, Weilbaecher KN West J Med 1994 Nov;161(5):513-5
Culture of Phenotypically Defined Hematopoietic Stem Cells and Other Progenitors at Limiting Dilution on Dexter Monolayers Weilbaecher K, Weissman I, Blume K, Heimfeld S Blood 1991 Aug;78(4):945-52
Long-Term Human Hematopoiesis in the SCID-Hu Mouse Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM J Exp Med 1990 Oct;172(4):1055-63
Lineage Specificity of Rearrangement and Expression of Genes Encoding the T Cell Receptor-T3 Complex and Immunoglobulin Heavy Chain in Leukemia Furley AJ, Chan LC, Mizutani S, Ford AM, Weilbaecher K, Pegram SM, Greaves MF Leukemia 1987 Sep;1(9):644-52
Developmentally Regulated Rearrangement and Expression of Genes Encoding the T Cell Receptor-T3 Complex Furley AJ, Mizutani S, Weilbaecher K, Dhaliwal HS, Ford AM, Chan LC, Molgaard HV, Toyonaga B, Mak T, van den Elsen P, et al. Cell 1986 Jul;46(1):75-87